합성생물학 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 기술별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Synthetic Biology Market Growth & Trends:

The global synthetic biology market size is expected to reach USD 42.06 billion by 2030, registering a CAGR of 17.30% 2025 to 2030, according to a new report by Grand View Research, Inc. The presence of government and private funding to support research in vaccines and a strong synthetic biologic-based product pipeline in clinical trials are the key driving factors for the market. Synthetic biology processes provide crucial advantages for producing antigen and diagnostic reagents for disease identification, accelerating the speed of vaccine development, and improving overall vaccine performance and yield.

Furthermore, support from government agencies and the presence of several programs are likely to boost the market growth. For instance, in the U.S., COVID-19 vaccine R&D, manufacture, regulation, and purchase have been highly supported by collaboration between federal agencies, including the Biomedical Advanced Research and Development Authority (BARDA), the National Institutes of Health (NIH), DOD, FDA, and others (formerly OWS).

Other factors such as expanding demand in industries such as textiles and nutrition are also contributing to the market growth. Several optimal food production processes have been identified with the help of synthetic biology. In addition, synthetic biology is predicted to aid in the generation of higher agricultural yields and pest control development. It is expected to help in the production of better food yield and pest control management.

The COVID-19 pandemic is anticipated to positively impact market growth. Synthetic biology has been highlighted as a means to accelerate vaccine development by the National Institute of Health in the U.S. Therefore, synthetic biology labs and companies have been actively utilizing this technology to combat the COVID-19 pandemic. As a result, the usage of these technologies is projected to increase during the outbreak.

The growing demand for personalized medicine is expected to majorly drive market growth during the coming years. The use of engineered novel proteins for use as therapeutics has demonstrated synthetic biology in the medical segment. These proteins are designed with some modified protein structure to get the desirable properties required for the treatment. For instance, researchers are developing a therapeutic enzyme candidate that is GI-stable and can be given via oral route to treat Phenylketonuria (PKU).

On the other hand, synthetic biology has raised a few concerns regarding biosecurity and biosafety. Exposure to these products may cause unknown hazards to public health and the environment. To prevent such issues, countries of Europe, the Americas, and Asia have formulated policies to manage the application of synthetic biology techniques in basic & applied research.

Synthetic Biology Market Report Highlights:

• By technology, the PCR segment held the largest share of the market. This is attributed to the accelerated development in modern life science, with PCR technology being widely employed in numerous fields of medical research, virus detection, and the food & beverage industry
• The genome-editing segment is expected to grow steadily during the forecast period. It enables researchers to modify the DNA of various organisms, including plants, bacteria, and animals, and their demand is expected to skyrocket in the coming years
• By product, Oligonucleotide and Synthetic DNA is anticipated to have the larger market share in 2030. The falling price of synthesis and increasing requirement for synthetic DNA, RNA, and genes that are employed in numerous applications contribute to the segment growth
• By application, the healthcare segment held a larger global market share. This is attributed to an increase in drug screening and discovery. Moreover, the use of synthetic biology can reduce the cost of drug discovery and propel market growth
• By end-user, the biotechnology and pharmaceutical companies segment held a larger share in 2024, owing to the growing availability of modern research facilities, favorable legislation, and government assistance and funding
• North America was positioned as the dominant market in 2024 due to the presence of high R&D investment, the availability of technologically advanced healthcare research frameworks, and the development of the synthetic biology market in the region
• The Asia Pacific is expected to witness considerable growth in the future owing to the rising development of personalized treatment and the presence of key players

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Product Segment
  • 1.2.2. Technology Segment
  • 1.2.3. Application Segment
  • 1.2.4. End Use Segment
• 1.3. Information Analysis
  • 1.3.1. Market Formulation & Data Visualization
• 1.4. Data Validation & Publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Trends and Outlook
• 3.3. Market Dynamics
  • 3.3.1. Increasing Applications of Synthetic Biology
  • 3.3.2. Growing Funding and Assistance from Government and Private Organization
  • 3.3.3. Growing Research and Development Activities in Synthetic Biology
• 3.4. Market Restraint Analysis
  • 3.4.1. Biosafety and Biosecurity Issue
  • 3.4.2. Ethical Issues and Unintended Consequences
• 3.5. Industry Analysis Tools
  • 3.5.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
  • 3.5.2. Porter's Five Forces Analysis
  • 3.5.3. COVID-19 Impact Analysis

Chapter 4. Product Business Analysis

• 4.1. Product Segment Dashboard
• 4.2. Global Synthetic Biology Market: Product Movement Analysis
• 4.3. Global Synthetic Biology Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Oligonucleotide/Oligo pools and Synthetic DNA
  • 4.4.1. Oligonucleotide/Oligo pools and Synthetic DNA Market, 2018 - 2030 (USD Million)
• 4.5. Enzymes
  • 4.5.1. Enzymes Market, 2018 - 2030 (USD Million)
• 4.6. Cloning Technologies Kits
  • 4.6.1. Cloning Technologies Kits Market, 2018 - 2030 (USD Million)
• 4.7. Xeno-nucleic Acids
  • 4.7.1. Xeno-nucleic Acids Market, 2018 - 2030 (USD Million)
• 4.8. Chassis Organism
  • 4.8.1. Chassis Organism Market, 2018 - 2030 (USD Million)

Chapter 5. Technology Business Analysis

• 5.1. Technology Segment Dashboard
• 5.2. Global Synthetic Biology Market: Technology Movement Analysis
• 5.3. Global Synthetic Biology Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
• 5.4. PCR
  • 5.4.1. PCR Market, 2018 - 2030 (USD Million)
• 5.5. Genome Editing
  • 5.5.1. Genome Editing Market, 2018 - 2030 (USD Million)
• 5.6. NGS
  • 5.6.1. NGS Market, 2018 - 2030 (USD Million)
• 5.7. Bioprocessing Technology
  • 5.7.1. Bioprocessing Technology Market, 2018 - 2030 (USD Million)
• 5.8. Others
  • 5.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Application Business Analysis

• 6.1. Application Segment Dashboard
• 6.2. Global Synthetic Biology Market: Application Movement Analysis
• 6.3. Global Synthetic Biology Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 6.4. Synthetic Biology Market: Technology Movement Analysis
• 6.5. Healthcare
  • 6.5.1. Healthcare Market, 2018 - 2030 (USD Million)
  • 6.5.2. Clinical
    • 6.5.2.1. Clinical Market, 2018 - 2030 (USD Million)
    • 6.5.2.2. Bio/Pharmaceuticals
      • 6.5.2.2.1. Bio/Pharmaceuticals Market, 2018 - 2030 (USD Million)
    • 6.5.2.3. Diagnostics
      • 6.5.2.3.1. Diagnostics Market, 2018 - 2030 (USD Million)
  • 6.5.3. Non-Clinical
    • 6.5.3.1. Non-Clinical Market, 2018 - 2030 (USD Million)
• 6.6. Non-Healthcare
  • 6.6.1. Non-Healthcare Market, 2018 - 2030 (USD Million)
  • 6.6.2. Biotech Crops
    • 6.6.2.1. Biotech Crops Market, 2018 - 2030 (USD Million)
  • 6.6.3. Specialty Chemicals
    • 6.6.3.1. Specialty Chemicals Market, 2018 - 2030 (USD Million)
  • 6.6.4. Bio-Fuels
    • 6.6.4.1. Bio-Fuels Market, 2018 - 2030 (USD Million)
  • 6.6.5. Others
    • 6.6.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. End Use Business Analysis

• 7.1. End Use Segment Dashboard
• 7.2. Global Synthetic Biology Market: End Use Movement Analysis
• 7.3. Global Synthetic Biology Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 7.4. Biotechnology and Pharmaceutical Companies
  • 7.4.1. Biotechnology and Pharmaceutical Companies Market, 2018 - 2030 (USD Million)
• 7.5. Academic & Research Institutes
  • 7.5.1. Academic & Research Institutes Market, 2018 - 2030 (USD Million)
• 7.6. Others
  • 7.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. Regional Business Analysis

• 8.1. Regional Dashboard
• 8.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
• 8.3. North America
  • 8.3.1. North America Synthetic Biology Market, 2018 - 2030 (USD Million)
  • 8.3.2. U.S.
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Target Disease Prevalence
    • 8.3.2.3. Competitive Scenario
    • 8.3.2.4. Regulatory Framework
    • 8.3.2.5. U.S. Synthetic Biology Market, 2018 - 2030 (USD MILLION)
  • 8.3.3. Canada
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Target Disease Prevalence
    • 8.3.3.3. Competitive Scenario
    • 8.3.3.4. Regulatory Framework
    • 8.3.3.5. Canada Synthetic Biology Market, 2018 - 2030 (USD Million)
  • 8.3.4. Mexico
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Target Disease Prevalence
    • 8.3.4.3. Competitive Scenario
    • 8.3.4.4. Regulatory Framework
    • 8.3.4.5. Mexico Synthetic Biology Market, 2018 - 2030 (USD Million)
• 8.4. Europe
  • 8.4.1. Europe Synthetic Biology Market, 2018 - 2030 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Target Disease Prevalence
    • 8.4.2.3. Competitive Scenario
    • 8.4.2.4. Regulatory Framework
    • 8.4.2.5. Germany Synthetic Biology Market, 2018 - 2030 (USD Million)
  • 8.4.3. UK
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Target Disease Prevalence
    • 8.4.3.3. Competitive Scenario
    • 8.4.3.4. Regulatory Framework
    • 8.4.3.5. UK Synthetic Biology Market, 2018 - 2030 (USD Million)
  • 8.4.4. France
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Target Disease Prevalence
    • 8.4.4.3. Competitive Scenario
    • 8.4.4.4. Regulatory Framework
    • 8.4.4.5. France Synthetic Biology Market, 2018 - 2030 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Target Disease Prevalence
    • 8.4.5.3. Competitive Scenario
    • 8.4.5.4. Regulatory Framework
    • 8.4.5.5. Italy Synthetic Biology Market, 2018 - 2030 (USD Million)
  • 8.4.6. Spain
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Target Disease Prevalence
    • 8.4.6.3. Competitive Scenario
    • 8.4.6.4. Regulatory Framework
    • 8.4.6.5. Spain Synthetic Biology Market, 2018 - 2030 (USD Million)
  • 8.4.7. Denmark
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Target Disease Prevalence
    • 8.4.7.3. Competitive Scenario
    • 8.4.7.4. Regulatory Framework
    • 8.4.7.5. Denmark Synthetic Biology Market, 2018 - 2030 (USD Million)
  • 8.4.8. Sweden
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Target Disease Prevalence
    • 8.4.8.3. Competitive Scenario
    • 8.4.8.4. Regulatory Framework
    • 8.4.8.5. Sweden Synthetic Biology Market, 2018 - 2030 (USD Million)
  • 8.4.9. Norway
    • 8.4.9.1. Key Country Dynamics
    • 8.4.9.2. Target Disease Prevalence
    • 8.4.9.3. Competitive Scenario
    • 8.4.9.4. Regulatory Framework
    • 8.4.9.5. Norway Synthetic Biology Market, 2018 - 2030 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific Synthetic Biology Market, 2018 - 2030 (USD Million)
  • 8.5.2. Japan
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Target Disease Prevalence
    • 8.5.2.3. Competitive Scenario
    • 8.5.2.4. Regulatory Framework
    • 8.5.2.5. Japan Synthetic Biology Market, 2018 - 2030 (USD Million)
  • 8.5.3. China
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Target Disease Prevalence
    • 8.5.3.3. Competitive Scenario
    • 8.5.3.4. Regulatory Framework
    • 8.5.3.5. China Synthetic Biology Market, 2018 - 2030 (USD Million)
  • 8.5.4. India
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Target Disease Prevalence
    • 8.5.4.3. Competitive Scenario
    • 8.5.4.4. Regulatory Framework
    • 8.5.4.5. India Synthetic Biology Market, 2018 - 2030 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Target Disease Prevalence
    • 8.5.5.3. Competitive Scenario
    • 8.5.5.4. Regulatory Framework
    • 8.5.5.5. South Korea Synthetic Biology Market, 2018 - 2030 (USD Million)
  • 8.5.6. Australia
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Target Disease Prevalence
    • 8.5.6.3. Competitive Scenario
    • 8.5.6.4. Regulatory Framework
    • 8.5.6.5. Australia Synthetic Biology Market, 2018 - 2030 (USD Million)
  • 8.5.7. Thailand
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Target Disease Prevalence
    • 8.5.7.3. Competitive Scenario
    • 8.5.7.4. Regulatory Framework
    • 8.5.7.5. Thailand Synthetic Biology Market, 2018 - 2030 (USD Million)
• 8.6. Latin America
  • 8.6.1. Latin America Synthetic Biology Market, 2018 - 2030 (USD Million)
  • 8.6.2. Brazil
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Target Disease Prevalence
    • 8.6.2.3. Competitive Scenario
    • 8.6.2.4. Regulatory Framework
    • 8.6.2.5. Brazil Synthetic Biology Market, 2018 - 2030 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Target Disease Prevalence
    • 8.6.3.3. Competitive Scenario
    • 8.6.3.4. Regulatory Framework
    • 8.6.3.5. Argentina Synthetic Biology Market, 2018 - 2030 (USD Million)
• 8.7. MEA
  • 8.7.1. MEA Synthetic Biology Market, 2018 - 2030 (USD Million)
  • 8.7.2. South Africa
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Target Disease Prevalence
    • 8.7.2.3. Competitive Scenario
    • 8.7.2.4. Regulatory Framework
    • 8.7.2.5. South Africa Synthetic Biology Market, 2018 - 2030 (USD Million)
  • 8.7.3. Saudi Arabia
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Target Disease Prevalence
    • 8.7.3.3. Competitive Scenario
    • 8.7.3.4. Regulatory Framework
    • 8.7.3.5. Saudi Arabia Synthetic Biology Market, 2018 - 2030 (USD Million)
  • 8.7.4. UAE
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Target Disease Prevalence
    • 8.7.4.3. Competitive Scenario
    • 8.7.4.4. Regulatory Framework
    • 8.7.4.5. UAE Synthetic Biology Market, 2018 - 2030 (USD Million)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Target Disease Prevalence
    • 8.7.5.3. Competitive Scenario
    • 8.7.5.4. Regulatory Framework
    • 8.7.5.5. Kuwait Synthetic Biology Market, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2024
• 9.4. Participant's Overview
  • 9.4.1. Bota Biosciences Inc.
    • 9.4.1.1. Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Product Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. Codexis, Inc.
    • 9.4.2.1. Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Product Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. Creative Biogene
    • 9.4.3.1. Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Product Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. Creative Enzymes
    • 9.4.4.1. Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Product Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. Enbiotix, Inc.
    • 9.4.5.1. Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Product Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. Illumina, Inc.
    • 9.4.6.1. Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Product Benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. Merck KGaA
    • 9.4.7.1. Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Product Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. New England Biolabs
    • 9.4.8.1. Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Product Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. Eurofins Scientific
    • 9.4.9.1. Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Product Benchmarking
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. Novozymes
    • 9.4.10.1. Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Product Benchmarking
    • 9.4.10.4. Strategic Initiatives
  • 9.4.11. Pareto Bio, Inc.
    • 9.4.11.1. Overview
    • 9.4.11.2. Financial Performance
    • 9.4.11.3. Product Benchmarking
    • 9.4.11.4. Strategic Initiatives
  • 9.4.12. Scarab Genomics, Inc.
    • 9.4.12.1. Overview
    • 9.4.12.2. Financial Performance
    • 9.4.12.3. Product Benchmarking
    • 9.4.12.4. Strategic Initiatives
  • 9.4.13. Synthego
    • 9.4.13.1. Overview
    • 9.4.13.2. Financial Performance
    • 9.4.13.3. Product Benchmarking
    • 9.4.13.4. Strategic Initiatives
  • 9.4.14. Synthetic Genomics Inc.
    • 9.4.14.1. Overview
    • 9.4.14.2. Financial Performance
    • 9.4.14.3. Product Benchmarking
    • 9.4.14.4. Strategic Initiatives
  • 9.4.15. Thermo Fisher Scientific, Inc.
    • 9.4.15.1. Overview
    • 9.4.15.2. Financial Performance
    • 9.4.15.3. Product Benchmarking
    • 9.4.15.4. Strategic Initiatives